Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Dean W. Felsher"'
Autor:
Arvin M. Gouw, Aida S. Hansen, Wadie D. Mahauad-Fernandez, Renumathy Dhanasekaran, Anja Deutzmann, Dean W. Felsher
Publikováno v:
Nat Rev Clin Oncol
The MYC proto-oncogenes encode a family of transcription factors that are among the most commonly activated oncoproteins in human neoplasias. Indeed, MYC aberrations or upregulation of MYC-related pathways by alternate mechanisms occur in the vast ma
Autor:
Ling Tong, Jingjing Wang, Mariola Liebersbach, Sharon S. Hori, Dean W. Felsher, Sanjiv S. Gambhir, Srividya Swaminathan
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Scientific Reports
Scientific Reports
The targeted inactivation of individual oncogenes can elicit regression of cancers through a phenomenon called oncogene addiction. Oncogene addiction is mediated by cell-autonomous and immune-dependent mechanisms. Therapeutic resistance to oncogene i
Autor:
Alexandre Borrel, Keith A. Houck, Linda Rieswijk, Dean W. Felsher, Herve Lebrec, Hideko Sone, Martyn T. Smith, Mark R. Fielden, Nicole Kleinstreuer, Amy Wang, Luoping Zhang, William H. Goodson, Weihsueh A. Chiu, Leroy Lowe, Kathryn Z. Guyton, Sheroy Minocherhomji, Agnes B. Kane, Michele A. La Merrill, Andres Cardenas, Lauren Zeise, Cliona M. McHale, Martha S. Sandy, Catherine F. Gibbons
Publikováno v:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 29, iss 10
Cancer Epidemiol Biomarkers Prev
Cancer Epidemiology Biomarkers & Prevention, 29(10), 1887-1903. American Association for Cancer Research Inc.
Cancer Epidemiol Biomarkers Prev
Cancer Epidemiology Biomarkers & Prevention, 29(10), 1887-1903. American Association for Cancer Research Inc.
The key characteristics (KC) of human carcinogens provide a uniform approach to evaluating mechanistic evidence in cancer hazard identification. Refinements to the approach were requested by organizations and individuals applying the KCs. We assemble
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f725ef5f94efc15e3ae91c735cca5fc4
https://escholarship.org/uc/item/53g7v8nn
https://escholarship.org/uc/item/53g7v8nn
Autor:
Maya Krishnan, Mustafa A. Barbhuiya, Sibu P. Kuruvilla, Nia Adeniji, Phuoc T. Tran, Virginie Baylot, Ian Lai, Anand Rajan Kd, Meital Gabay, Dean W. Felsher, Theodore Hu, Andrew J. Gentles, Renumathy Dhanasekaran, David I. Bellovin, Ling Tong, Jangho Park, Minsoon Kim, Kasthuri Kannan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e3baba5b4bbaeaad534e1c2fd9f6541
https://doi.org/10.7554/elife.50731.sa2
https://doi.org/10.7554/elife.50731.sa2
Publikováno v:
Hepatology. 70:1056-1058
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in developed countries and its incidence is rapidly increasing. Cirrhosis, and the dreaded complication of hepatocellular carcinoma (HCC), are the major drivers of
Autor:
Ronan T, Swords, Peter L, Greenberg, Andrew H, Wei, Simon, Durrant, Anjali S, Advani, Mark S, Hertzberg, Brian A, Jonas, Ian D, Lewis, Gabriel, Rivera, Dita, Gratzinger, Alice C, Fan, Dean W, Felsher, Jorge E, Cortes, Justin M, Watts, Geoff T, Yarranton, Jackie M, Walling, Jeffrey E, Lancet
Publikováno v:
Leukemia Research. 50:123-131
EphA3 is an Ephrin receptor tyrosine kinase that is overexpressed in most hematologic malignancies. We performed a first-in-human multicenter phase I study of the anti-EphA3 monoclonal antibody KB004 in refractory hematologic malignancies in order to
Autor:
Yumi Miyazaki, Keiichi Sakurai, Yasushi Miura, Dean W. Felsher, Akira Hashiramoto, Shunichi Shiozawa, Ken Tsumiyama, Chiaki Uchimura, Eriko Honda, Chieri Akiyama
Publikováno v:
Journal of immunology (Baltimore, Md. : 1950). 203(4)
The cause of systemic lupus erythematosus (SLE) is unknown. IFN-α has been suggested as a causative agent of SLE; however, it was not proven, and to what extent and how IFN-α contributes to the disease is unknown. We studied the contribution of IFN
Publikováno v:
Oncotarget
Oncogene inactivation in both clinical targeted therapies and conditional transgenic mouse cancer models can induce significant tumor regression associated with the robust induction of apoptosis. Here we report that in MYC-, RAS-, and BCR-ABL-induced
Publikováno v:
Cancer Research. 80:B21-B21
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and the second most common acute leukemia in adults. Despite best existing therapy, older children and elderly ALL patients have poor prognoses. Thus, there is a need to identify
Autor:
Ian Lai, Renumathy Dhanasekaran, Virginie Baylot, Dean W. Felsher, Srividya Swaminathan, Adriane Mosley, Meital Gabay
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-11 (2018)
Interleukin-12 (IL-12) is a promising candidate for cancer immunotherapy because of its ability to activate a number of host immune subsets that recognize and destroy cancer cells. We found that human hepatocellular carcinoma (HCC) patients with high